Cardiovascular risk, hypertension, and NSAIDs

  title={Cardiovascular risk, hypertension, and NSAIDs},
  author={William B. White},
  journal={Current Rheumatology Reports},
  • W. White
  • Published 3 June 2007
  • Medicine, Biology
  • Current Rheumatology Reports
During the past 2 years, a great deal of evaluation has been conducted on the cardiovascular (CV) effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase (COX)-2 inhibitors. This review focuses on the effects of the NSAIDs and COX-2 inhibitors on blood pressure and CV events. Clinical trial databases for NSAIDs and COX-2 inhibitors have shown varying levels of destabilization of blood pressure control in treated hypertensive patients as well as variable incident… 

Safety of selective non-steroidal anti-inflammatory drugs: analysis of the last years data

A meta-analysis showed that relatively selective COX-2 inhibitors (meloxicam, etodolac) were associated with a comparable risk of developing symptomatic ulcers and ulcers identified by endoscopy, and safety and tolerance profiles of the drugs were similar.

Hypertension in rheumatoid arthritis.

The mechanisms that may lead to increased blood pressure in patients with RA are discussed, paying particular attention to commonly used drugs for the treatment of RA, and screening strategies and management algorithms for HT are suggested.

NSAID–antihypertensive drug interactions: Which outpatients are at risk for a rise in systolic blood pressure?

A newly initiated NSAID has an immediate clinically relevant effect on SBP in some users of antihypertensives, and management guidelines for NSAID-antihypertensive drug–drug interactions should advise SBP monitoring before and after initiation of an NSAID or intensification of NSAID therapy.


The costeffectiveness of conventional medicines such as non-steroidal anti-inflammatory drugs (NSAIDs) and celecoxib and complementary and alternative medicines (CAM) therapies to treat KOA is examined from the US health care payers’ and patients’ perspectives and from 24week, 2-year, and 10-year time-horizons.

Prevalence, awareness, treatment, and control of hypertension in older people: results from the population-based KORA-age 1 study

High prevalence of hypertension and relevant health gaps on awareness, treatment and suboptimal control of hypertension in older adults in Germany are identified and screening for hypertension should especially target older adults with low educational attainment and ‘healthy’ elderly with less contact to physicians.

Inhibition of nuclear factor kappaB activation and cyclooxygenase-2 expression by aqueous extracts of Hispanic medicinal herbs.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are a primary choice of therapy for diseases with a chronic inflammatory component. Unfortunately, long-term NSAID therapy is often accompanied by severe

The relation between total joint arthroplasty and risk for serious cardiovascular events in patients with moderate-severe osteoarthritis: propensity score matched landmark analysis

This study suggests that management of hip or knee osteoarthritis with arthroplasty decreases the risk for subsequent serious cardiovascular events.



Non-selective nonsteroidal anti-inflammatory drugs and cardiovascular events: is aldosterone the silent partner in crime?

The question remains whether inhibition of aldosterone metabolism by non-selective NSAIDs is a casual or causal factor in NSAID-induced cardiovascular toxicity.

Risk of cardiovascular events associated with selective COX-2 inhibitors.

The results from VIGOR showed that the relative risk of developing a confirmed adjudicated thrombotic cardiovascular event with rofecoxib treatment compared with naproxen was higher than that in the placebo group of a recent meta-analysis of 23 407 patients in primary prevention trials.

Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular Events

Use of NSAIDs or acetaminophen at high frequency or dose is associated with a significantly increased risk for major cardiovascular events, although more moderate use did not confer substantial risk.

Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition.

  • D. Brater
  • Medicine
    The American journal of medicine
  • 1999

Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction.

The findings suggest that the risk of AMI is increased during several weeks after the cessation of NSAID therapy, and was highest in subjects with rheumatoid arthritis or systemic lupus erythematosus.

Treating Osteoarthritis With Cyclooxygenase-2–Specific Inhibitors: What Are the Benefits of Avoiding Blood Pressure Destabilization?

It is concluded that even a small increase in systolic blood pressure among hypertensive Americans with osteoarthritis may substantially increase the clinical and economic burden of cardiovascular disease.

Effects of Celecoxib on Ambulatory Blood Pressure in Hypertensive Patients on ACE Inhibitors

It is demonstrated that high doses of celecoxib have no significant effect on the antihypertensive effect of the ACE inhibitor lisinopril, and changes in the 24-hour BP, body weight, and clinical laboratory parameters were assessed.

The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil.

The addition of naproxen or ibuprofen to the treatment of hypertensive patients in whom blood pressure is controlled by once-daily verapamil does not cause an increase in blood pressure, and Verapamils may offer considerable advantages in maintaining control of blood pressure in patients who regularly receive nonsteroidal anti-inflammatory drug therapy.

Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.

It is suggested that celecoxib in commonly used doses may not increase the risk, contradicts claims of a protective effect of naproxen, and raises serious questions about the safety of diclofenac, an older drug.